Eli Lilly shares see potential upside as Phase 3 trials for retatrutide show substantial efficacy in treating knee osteoarthritis and obesity, with some patients achieving complete pain relief.
Lilly announced that Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end. Positive pivotal data support the retatrutide pipeline and are a modest positive for Lilly shares, though the article gives no effect sizes, financial figures or guidance.
Phase 3 TRIUMPH-1 and TRIUMPH-4 results showed substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials.
The article does not mention any financial guidance change.
Eli Lilly announced positive Phase 3 results for its investigational drug retatrutide at the ACR Convergence 2026 conference. The TRIUMPH-1 and TRIUMPH-4 trials demonstrated significant reductions in both knee pain and body weight among patients suffering from obesity and knee osteoarthritis.
Phase 3 TRIUMPH-1 and TRIUMPH-4 results showed substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials.
The article does not mention any financial guidance change.